Floyd Buen, MD
Otolaryngology · Newport Beach, CANPI 1902291479
Payments from drug & device makers
Across 67 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$656
- Inspire Medical Systems, Inc.$168
- Intersect ENT, Inc.$147
- Stryker$112
- Sanofi$102
- Regeneron Healthcare Solutions, Inc.$87
- plus $311 from 9 others
What the payments were for
- Food & beverage$1,583100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 38 | $656 |
| Inspire Medical Systems, Inc. | 2 | $168 |
| Intersect ENT, Inc. | 5 | $147 |
| Stryker | 3 | $112 |
| Sanofi | 4 | $102 |
| Regeneron Healthcare Solutions, Inc. | 3 | $87 |
| GSK | 3 | $78 |
| Smith+Nephew | 2 | $58 |
| Aroa Biosurgery Incorporated | 1 | $34 |
| Boston Scientific | 1 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Integra Lifesciences Corporation | 1 | $23 |
| Aerin Medical Inc. | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Neurent Medical Limited | 1 | $18 |
How this compares
$1,583 in reported general payments places this provider in the 55th percentile of 1,021 otolaryngology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 161 | $8,160 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 43 | $2,290 |
| Fluocinolone Acetonide Oil | 56 | $2,196 |
| Azelastine Hcl | 89 | $1,621 |
| Cefdinir | 41 | $831 |
| Fluticasone Propionate | 53 | $773 |
| Triamcinolone Acetonide | 12 | $760 |
| Ofloxacin | 13 | $345 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 42 | $339 |
| Doxycycline Monohydrate | 12 | $191 |
| Gabapentin | 13 | $147 |
| Hydrocortisone | 38 | $140 |
| Methylprednisolone | 17 | $103 |
| Omeprazole | 17 | $101 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $88 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Newport Beach
- Todd MillerNewport Beach$259K
- Randall OwRoseville$4.3M
- Amir MoradiVista$2.6M
- Brian WeeksSan Diego$1.6M
- Charles LimbSan Francisco$1.5M
- Andrew BerosSan Diego$688K
- Paul SchalchChula Vista$573K
- Steven DavisTorrance$544K
- Arnaud BewleySacramento$541K
- Keith BlackwellLos Angeles$349K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.